Needle-free delivery of DNA : Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved..
Conventional influenza vaccines are hampered by slow and limited production capabilities, whereas DNA vaccines can be rapidly produced for global coverage in the event of an emerging pandemic. However, a drawback of DNA vaccines is their generally low immunogenicity in non-human primates and humans. We have previously demonstrated that targeting of influenza hemagglutinin to human HLA class II molecules can increase antibody responses in larger animals such as ferrets and pigs. Here, we extend these observations by immunizing non-human primates (rhesus macaques) with a DNA vaccine encoding a bivalent fusion protein that targets influenza virus hemagglutinin (HA) to Mamu class II molecules. Such immunization induced neutralizing antibodies and antigen-specific T cells. The DNA was delivered by pain- and needle-free jet injections intradermally. No adverse effects were observed. Most importantly, the immunized rhesus macaques were protected against a challenge with influenza virus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Vaccine - 37(2019), 6 vom: 04. Feb., Seite 817-826 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mooij, Petra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.07.2020 Date Revised 07.07.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2018.12.049 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292669399 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292669399 | ||
| 003 | DE-627 | ||
| 005 | 20231225073625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2018.12.049 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0975.xml |
| 035 | |a (DE-627)NLM292669399 | ||
| 035 | |a (NLM)30638800 | ||
| 035 | |a (PII)S0264-410X(19)30005-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mooij, Petra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Needle-free delivery of DNA |b Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2020 | ||
| 500 | |a Date Revised 07.07.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Conventional influenza vaccines are hampered by slow and limited production capabilities, whereas DNA vaccines can be rapidly produced for global coverage in the event of an emerging pandemic. However, a drawback of DNA vaccines is their generally low immunogenicity in non-human primates and humans. We have previously demonstrated that targeting of influenza hemagglutinin to human HLA class II molecules can increase antibody responses in larger animals such as ferrets and pigs. Here, we extend these observations by immunizing non-human primates (rhesus macaques) with a DNA vaccine encoding a bivalent fusion protein that targets influenza virus hemagglutinin (HA) to Mamu class II molecules. Such immunization induced neutralizing antibodies and antigen-specific T cells. The DNA was delivered by pain- and needle-free jet injections intradermally. No adverse effects were observed. Most importantly, the immunized rhesus macaques were protected against a challenge with influenza virus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a APC-targeted antigen | |
| 650 | 4 | |a Antigen presenting cell | |
| 650 | 4 | |a DNA vaccine | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Non-human primates | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Hemagglutinin Glycoproteins, Influenza Virus |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class II |2 NLM | |
| 650 | 7 | |a Vaccines, DNA |2 NLM | |
| 650 | 7 | |a Viral Fusion Proteins |2 NLM | |
| 700 | 1 | |a Grødeland, Gunnveig |e verfasserin |4 aut | |
| 700 | 1 | |a Koopman, Gerrit |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Tor Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Mortier, Daniella |e verfasserin |4 aut | |
| 700 | 1 | |a Nieuwenhuis, Ivonne G |e verfasserin |4 aut | |
| 700 | 1 | |a Verschoor, Ernst J |e verfasserin |4 aut | |
| 700 | 1 | |a Fagrouch, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Bogers, Willy M |e verfasserin |4 aut | |
| 700 | 1 | |a Bogen, Bjarne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 37(2019), 6 vom: 04. Feb., Seite 817-826 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2019 |g number:6 |g day:04 |g month:02 |g pages:817-826 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2018.12.049 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2019 |e 6 |b 04 |c 02 |h 817-826 | ||